To review the current literature regarding the effectiveness and risks of new surgeries that can be combined with phacoemulsification in the management of cataract and glaucoma.
INTRODUCTION
Cataract and glaucoma frequently coexist in our elderly patient population. It has been estimated that 20% of cataract procedures are performed annually in the USA in individuals with comorbid glaucoma and ocular hypertension. Phacoemulsification combined with trabeculectomy has historically been the preferred surgical approach for concurrently managing cataract and glaucoma. However, a growing concern about intraoperative and postoperative complications associated with trabeculectomy has prompted many surgeons to explore alternative procedures. Several new glaucoma procedures have been introduced into clinical practice which may be performed in conjunction with cataract surgery [1 && ]. Recent studies have evaluated the safety and efficacy of endoscopic cyclophotocoagulation (ECP), trabecular micro-bypass stent (iStent), ab interno trabeculectomy (Trabectome), and canaloplasty combined with phacoemulsification. Most of these studies consist of retrospective case series that lack a control group. Retrospective [2] and prospective [3 && ] studies have shown that cataract surgery alone may result in a modest (2-3 mmHg) reduction in intraocular pressure (IOP). Therefore, determination of the relative contribution of a glaucoma procedure in lowering the IOP requires prospective comparison with a control group consisting of cataract surgery alone. Unfortunately, randomized clinical trials that assess the new glaucoma procedures are generally lacking. The purpose of this article is to provide an evidence-based review of the new options for combined cataract and glaucoma surgery.
ECP is a newer method of cyclophotocoagulation involving laser treatment of the ciliary processes under direct visualization. ECP has been used in the management of refractory glaucomas and pediatric patients, but it is most commonly performed in combination with phacoemulsification in eyes with medically controlled or uncontrolled glaucoma.
Efficacy
Despite the availability of ECP since the mid-1990s, its benefit in reducing the IOP when combined with phacoemulsification has not been clearly demonstrated. Most studies reporting the outcomes of phacoemulsification-ECP are retrospective case series that lack a control group [4
A randomized clinical trial comparing phacoemulsification alone with phacoemulsification-ECP would help to clarify the efficacy of phacoemulsification-ECP (Table 1) .
A prospective randomized trial compared phacoemulsification-ECP to phacoemulsificationtrabeculectomy (48% of cases received adjunctive mitomycin C) in a relatively small number of patients (29 in each treatment group) [10] . A higher success rate (IOP <19 mmHg without glaucoma medications) was observed after phacoemulsification-trabeculectomy (42%) compared with phacoemulsification-ECP (30%) with a mean follow-up of 2 years. A retrospective study compared phacoemulsification-ECP in 626 eyes to phacoemulsification alone in 81 eyes [9] . The methodology for this investigation was not described, including the criteria used for unequal matching of eyes (approximately 8 : 1). Mean IOP decreased by 17.6% in the phacoemulsification-ECP group with an associated 57.5% decrease in the mean number of glaucoma medications, and mean IOP increased by 4.2% in the phacoemulsification group without a change in the mean number of glaucoma medications with an average follow-up of 3.2 years.
Most surgeons suggest that ECP results in a mildto-moderate decrease in IOP and medical therapy. IOP reduction ranging from 17.6 to 57% has been reported following phacoemulsification-ECP. These highly variable results may relate to differences in study populations, length of follow-up, and treatment protocol (i.e., degrees of laser application, ECP through the bag or under the intraocular lens,
KEY POINTS
Glaucoma and elevated IOP are common in patients undergoing cataract surgery.
Endoscopic cyclophotocoagulation (ECP), trabecular micro-bypass stent (iStent), ab interno trabeculectomy (Trabectome), and canaloplasty are newer glaucoma procedures that may be performed in conjunction with phacoemulsification.
Because phacoemulsification can produce intraocular pressure (IOP) reduction, studies evaluating the efficacy of combined cataract and glaucoma procedures should include a comparison group of phacoemulsification alone.
The newer glaucoma procedures appear less effective in lowering IOP than trabeculectomy, but they are associated with fewer surgical complications. ECP with or without scleral indentation, and cessation or continuation of medical therapy). The long-term results of phacoemulsification-ECP are not well known, and concern exists that the IOP-lowering effect of ECP may diminish over time [11] . A histopathologic study demonstrated that ECP causes localized shrinkage of ciliary processes and reduction in blood flow with partial reperfusion by 1 month [12] . It has been speculated that the partial return of blood flow may lead to an increase in aqueous production with a corresponding rise in IOP. The need to retreat an eye with ECP after an initial effect may be explained by this phenomenon.
Surgical complications
The safety profile of ECP in the existing medical literature is varied and likely relates to the glaucoma subtype treated [13 && ]. Surgical complications observed in a large series of 368 eyes treated with phacoemulsification-ECP included IOP spike (14.4%), postoperative fibrin exudates in anterior chamber (7.06%), cystoid macular edema (4.34%), transient hypotony (2.17%), and iris bombé (1.08%) [6] . Lower rates of surgical complications have been reported with micro-invasive glaucoma surgery (MIGS) [1 && ]. Additionally, the pressure-lowering effect of cyclodestruction cannot be reversed in patients with hypotony-related sequelae.
Conclusion
Limited data exist in the peer-reviewed literature describing the efficacy and safety of phacoemulsification-ECP. A randomized clinical trial comparing phacoemulsification-ECP to phacoemulsification alone is needed to better evaluate this technique, and current information about the benefit of phacoemulsification-ECP is mostly uncontrolled.
COMBINED PHACOEMULSIFICATION AND iSTENT
The trabecular meshwork micro-bypass stent (iStent, Glaukos, Corp., Laguna Hills, California, USA) is a titanium implant that is inserted into Schlemm's canal through the trabecular meshwork internally. The implant is designed to shunt fluid from the anterior chamber into Schlemm's canal, bypassing the trabecular meshwork. The device is placed after completion of cataract surgery, so that the anterior chamber is maximally deep and so that it does not get dislodged during the phacoemulsification procedure.
Efficacy
There have been several studies of cataract surgery combined with iStent, some of which have a comparison group of patients undergoing cataract surgery alone. In the longest and largest prospective randomized clinical trial of the iStent conducted by Samuelson and colleagues [14,15 && ], iStent combined with phacoemulsification produced IOP lowering similar to phacoemulsification alone at 1 year [14] . However, IOP was controlled on 1-2 fewer medications than before surgery [14] . At 2 years, the differential effect of phacoemulsification-iStent compared with phacoemulsification alone is more pronounced, as the IOP-lowering effect of cataract surgery diminishes [15 && ]. Although the iStent only lowered pressure by 8% in this study, the effect on number of medications used was profound, with an over 80% reduction in medications out to 24 months (Table 2) .
Studies by Spiegel [18] and Fea [16] have shown an approximately 20% reduction in IOP after a 
Conclusion
iStent performed with cataract surgery is a safe procedure, but it offers little additional IOP-lowering effect compared with cataract surgery alone. Its main advantage appears to be in the reduction in hypotensive medication use. The pivotal randomized prospective trial comparing phacoemulsification-iStent to phacoemulsification alone provides the best information on the efficacy of the procedure and serves as a model for future trials of devices such as this. Second and third generation designs may provide additional IOP-lowering effects.
COMBINED PHACOEMULSIFICATION AND TRABECTOME
Ab interno trabeculotomy, also known as Trabectome (NeoMedix, Tustin, California, USA), is a new procedure in which sections of the trabecular meshwork are ablated using electrocautery delivered by a probe introduced through the anterior chamber. The amount of trabecular meshwork that is ablated varies depending on the exposure and visualization, but typically is 3-4 clock hours. When combined with cataract surgery, the Trabectome is typically delivered prior to phacoemulsification as excellent visualization is needed to perform the procedure and corneal clarity may be reduced after phacoemulsification, making visualization difficult.
Efficacy
Several studies have demonstrated that phacoemulsification-Trabectome lowers IOP by about 4-7 mmHg [20-22, ]. Specifically, patients with high preoperative IOPs may have a large IOP-lowering effect from phacoemulsification, whereas those with a low IOP may have little to no effect. So the comparison of combined phacoemulsificationTrabectome to phacoemulsification alone does not seem valid in this study. In addition, the change in medical therapy in the phacoemulsification alone group was not reported. The investigators performed a subanalysis in which they matched 10 patients from each group on baseline IOP and compared the results. The phacoemulsificationTrabectome patients averaged 25% lower IOP, and the phacoemulsification alone group had a 5% rise in IOP at 12 months. A randomized clinical trial would allow a better comparison of phacoemulsification-Trabectome and phacoemulsification alone (Table 3) .
Complications
Transient hyphema and postoperative elevation of IOP are the main complications of Trabectome combined with phacoemulsification, as with Trabectome alone. The mechanism, extent, and duration of the IOP elevation following Trabectome are unknown and unpredictable, adding some uncertainty to the postoperative management of these patients.
Conclusion
There is inconclusive evidence that Trabectome added to phacoemulsification has better IOP-lowering effect compared with phacoemulsification alone. Prospective randomized clinical trials are needed to demonstrate this. However, the procedure seems to lower IOP better than IOP-matched controls and the complications are minimal.
COMBINED PHACOEMULSIFICATION AND CANALOPLASTY
Canaloplasty is an ab externo procedure during which Schlemm's canal is cannulated with a fiber optic probe (iScience International, Menlo Park, California, USA), and a suture is then introduced 3608 and tightened until the trabecular meshwork is put on adequate stretch to improve aqueous humor outflow. Ideally, high-resolution ultrasound is used to confirm that the tissues of interest are properly stretched. The procedure is technically more difficult than those previously described and has the additional disadvantage of causing conjunctival scarring, which makes subsequent glaucoma surgery less successful and technically more difficult. An additional disadvantage is the expense of the equipment that is needed to perform the operation.
Efficacy
Combined phacoemulsification-canaloplasty was shown to lower IOP by approximately 40% in three studies [25] [26] [27] . The remarkably similar results of these studies may be because of pooling of data from the same patients in all three reports. None of the studies used a comparison group of phacoemulsification alone. A more recent small independent study by Matlach et al. [28 & ], also without a comparison group of phacoemulsification alone patients, found an average 55% drop in IOP after 12 months. In the only study to date comparing phacoemulsification-canaloplasty to phacoemulsification alone, Arthur et al. [29 && ] have reported a more profound IOP-lowering effect of the combined procedure throughout 24 months, although half to two-thirds of patients were lost to follow-up. The study was retrospective, so there was no randomization and the starting IOPs were relatively low in each group (16.2 in the phacoemulsification group and 18.2 in the phacoemulsification-canaloplasty group). In addition, the phacoemulsification-canaloplasty group started with mean baseline IOPs that were 2 mmHg higher than in the phacoemulsification group. Although there was no statistically significant difference in IOP at baseline or 24 months, patients in the combined group were on fewer medications and were less likely to fail by the standard criteria as outlined in the Tube vs. Trabeculectomy Study [30] (Table 4) . 
Complications
Transient hyphema, inadvertent filtering bleb, Descemet's detachment, and suture erosion through the trabecular meshwork may be seen after phacoemulsification-canaloplasty. In addition, suture placement within the canal may not be possible in approximately 15-25% of patients [25, 26] .
Conclusion
Phacoemulsification-canaloplasty appears to be more effective at lowering IOP than phacoemulsification alone and may be an effective and well tolerated alternative to phacoemulsification-trabeculectomy. Negative aspects of this procedure include its technical difficulty and the creation of conjunctival scarring which could limit the success of subsequent trabeculectomy. Although rare so far, there is also concern over possible long-term erosion of the suture used in canaloplasty into the anterior chamber because of constant tension on the trabecular meshwork.
CONCLUSION
The surgical options for concurrently managing cataract and glaucoma have expanded in recent years. Canaloplasty, Trabectome, iStent, and ECP may be performed in conjunction with phacoemulsification to provide additional IOP reduction and reduce the burden of glaucoma medical therapy. These new procedures appear to be less effective than trabeculectomy. However, they offer a more favorable safety profile with a lower risk of surgical complications. The role of newer glaucoma procedures in glaucoma management remains the subject of debate; however, they are most appropriately combined with phacoemulsification in patients with mild glaucomatous damage in whom low levels of IOP are not needed. Phacoemulsification-ECP has the advantage of ease of performance and lack of conjunctival scarring associated with the procedure. However, the modest IOP-lowering effect, variable and unpredictable response, and inability to reverse its effect make phacoemulsification-ECP a less desirable alternative than traditional or other new glaucoma procedures. iStent and Trabectome, when combined with phacoemulsification, seem to provide little IOP lowering compared with phacoemulsification alone. Their main advantage appears to be in the ability to reduce the medication burden of patients. Each procedure has different kinds of complications that must be taken into account when recommending one or the other procedure, but iStent and Trabectome, when combined with phacoemulsification, have the least serious complications.
